Antibody-Drug Conjugates Are ‘Changing Outcomes’ in HR+ HER2– Breast Cancer

Video

Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.

At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Sara M. Tolaney, MD, MPH, spoke with CancerNetwork® about how findings from the phase 3 TROPiCS-02 study (NCT03901339) highlight the ability of sacituzumab govitecan-hziy (Trodelvy) to improve patient outcomes over chemotherapy among those with hormone receptor–positive, HER2-negative metastatic breast cancer.

Tolaney, chief of the Division of Breast Oncology and associate director of the Susan F. Smith Center for Women’s Cancer at Dana-Farber Cancer Institute, and associate professor of medicine at Harvard Medical School, in Boston, discussed the low response rates and short duration of disease control associated with single agent chemotherapy in the aforementioned population.

In the TROPiCs-02 study, investigators reported a median overall survival (OS) of 14.5 months with sacituzumab vs 11.2 months with chemotherapy of physician’s choice (Hazard ratio, 0.79; 95% CI, 0.65-0.95; P = .0133).Additionally, the 12-month, 18-month, and 24-month OS rates among patients receiving sacituzumab vs those receiving chemotherapy were 60.9% (95% CI, 54.8%-66.4%) vs47.1% (95% CI, 41.0%-53.0%), 39.2% (95% CI, 33.4%-45.0%) vs 31.7% (95% CI, 26.2%-37.4%), and 25.6% (95% CI, 20.4%-31.2%) vs 21.1% (95% CI, 16.3%-26.3%), respectively.

Transcript:

It's really exciting to see that antibody-drug conjugates are changing outcomes for patients. We've been so used to seeing single agent chemotherapy being given sequentially in this pretreated setting, and, unfortunately, it has been associated with low response rates and short duration of disease control.

These data looking at sacituzumab can tell us that we do have new agents that do better than standard chemotherapy and are really improving outcomes for our patients.

Reference

Tolaney SM, Bardia A, Marmé F, et al. Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC). J Clin Oncol. 2023;41(suppl 16):1003. doi:10.1200/JCO.2023.41.16_suppl.1003

Recent Videos
Artificial intelligence may have the potential to enrich pathology practices to help identify aspects of tumor biology not seen with the human eye.
Efficacy results from the MASAI trial preceded the creation of the UK-funded EDITH trial, assessing 5 AI platforms in 700,000 women undergoing mammography.
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Findings from the phase 2b ReNeu trial show significant pain relief with mirdametinib in adult and pediatric patients with NF1-PN.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
The dispersible tablet formulation of mirdametinib may offer convenience to patients with NF1-PN and difficulty with swallowing pills.
Sotorasib plus panitumumab may offer improved survival compared with previously approved treatment options in KRAS G12C-mutated colorectal cancer.
Related Content